The Experts below are selected from a list of 27960 Experts worldwide ranked by ideXlab platform
Ralph M. Trüeb - One of the best experts on this subject based on the ideXlab platform.
-
Serum Biotin Levels in Women Complaining of Hair Loss.
International journal of trichology, 2016Co-Authors: Ralph M. TrüebAbstract:Biotin is a coenzyme for carboxylase enzymes that assist various metabolic reactions involved in fatty acid synthesis, branched-chain amino acid catabolism, and gluconeogenesis important for maintenance of healthy skin and Hair. Due to its availability, affordability, and effective marketing for this purpose, biotin is a popular nutritional supplement for treatment of Hair Loss. However, there are little data on the frequency of biotin deficiency in patients complaining of Hair Loss and on the value of oral biotin for treatment of Hair Loss that is not due to an inborn error of biotin metabolism or deficiency. The aim of this study was to determine the frequency and significance of biotin deficiency in women complaining of Hair Loss. Biotin deficiency was found in 38% of women complaining of Hair Loss. Of those showing diffuse telogen effluvium in trichograms (24%), 35% had evidence of associated seborrheic-like dermatitis. About 11% of patients with biotin deficiency had a positive personal history for risk factors for biotin deficiency. The custom of treating women complaining of Hair Loss in an indiscriminate manner with oral biotin supplementation is to be rejected, unless biotin deficiency and its significance for the complaint of Hair Loss in an individual has been demonstrated on the basis of a careful patient history, clinical examination, determination of serum biotin levels, and exclusion of alternative factors responsible for Hair Loss.
-
Systematic approach to Hair Loss in women
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010Co-Authors: Ralph M. TrüebAbstract:Diffuse Hair Loss is a common complaint and cause of significant emotional distress particularly in women. The best way to alleviate the anxiety is to effectively treat the Hair Loss. It is paramount to address the symptom systematically. In addition to its psychological impact, Hair Loss may be a manifestation of a more general medical problem. The diagnosis can be established with a detailed patient history focussing on chronology of events, examination of the scalp and pattern of Hair Loss, a pull test with examination of bulbs of shed Hairs, trichoscopy, and few pertinent screening blood tests. In selected cases a scalp biopsy may be required. The most important differential diagnoses include acute and chronic telogen effluvium, female pattern Hair Loss, and diffuse alopecia areata. Occasionally, patients seeking advice are not necessarily losing Hair. In the absence of convincing evidence of Hair Loss, they are suffering of psychogenic pseudoeffluvium, and thought should be given to an underlying psychological disorder. Once the diagnosis is established, treatment appropriate for that diagnosis is likely to control the Hair Loss. Finally, appropriate psychological support and education about the basics of the Hair cycle, and why considerable patience is required for effective cosmetic recovery, are essential to help limit patient anxiety.
-
Chemotherapy-induced Hair Loss.
Skin therapy letter, 2010Co-Authors: Ralph M. TrüebAbstract:Chemotherapy-induced Hair Loss occurs with an estimated incidence of 65%. Forty-seven percent of female patients consider Hair Loss to be the most traumatic aspect of chemotherapy and 8% would decline chemotherapy due to fears of Hair Loss. At present, no approved pharmacologic intervention exists to circumvent this side-effect of anticancer treatment, though a number of agents have been investigated on the basis of the current understanding of the underlying pathobiology. Among the agents that have been evaluated, topical minoxidil was able to reduce the severity or shorten the duration, but it did not prevent Hair Loss. The major approach to minimize chemotherapy-induced Hair Loss is by scalp cooling, though most published data on this technique are of poor quality. Fortunately, the condition is usually reversible, and appropriate Hair and scalp care along with temporarily wearing a wig may represent the most effective coping strategy. However, some patients may show changes in color and/or texture of regrown Hair, and in limited cases the reduction in density may persist.
-
Diffuse Hair Loss
Hair Growth and Disorders, 1Co-Authors: Ralph M. TrüebAbstract:• Many factors can lead to pathologically increased Hair Loss. The pathologic dynamics of Hair Loss can be related to disorders of Hair cycling.
Andrei V. Gudkov - One of the best experts on this subject based on the ideXlab platform.
-
p53 Is Essential for Chemotherapy-induced Hair Loss
Cancer research, 2000Co-Authors: Vladimir A. Botchkarev, Elena A. Komarova, Frank Siebenhaar, Natalia V. Botchkareva, Pavel G. Komarov, Marcus Maurer, Barbara A. Gilchrest, Andrei V. GudkovAbstract:Anticancer drugs stimulate apoptosis in the Hair follicles (HF) and cause Hair Loss, the most common side effect of chemotherapy. In a mouse model for chemotherapy-induced Hair Loss, we demonstrate that p53 is essential for this process: in contrast to wild-type mice, p53-deficient mice show neither Hair Loss nor apoptosis in the HF keratinocytes that maintained active proliferation after cyclophosphamide treatment. HF in p53 mutants are characterized by down-regulation of Fas and insulin-like growth factor-binding protein 3 and by increased expression of Bcl-2. These observations indicate that local pharmacological inhibition of p53 may be useful to prevent chemotherapy-associated Hair Loss.
Rodney Sinclair - One of the best experts on this subject based on the ideXlab platform.
-
Drugs and Hair Loss
Dermatologic clinics, 2012Co-Authors: Mansi Patel, Shannon Harrison, Rodney SinclairAbstract:Hair Loss is a common complaint, both in men and women, and use of prescription medications is widespread. When there is a temporal association between the onset of Hair Loss and commencement of a medication, the medication is commonly thought to have caused the Hair Loss. However, Hair Loss and in particular telogen effluvium may occur in response to a number of triggers including fever, hemorrhage, severe illness, stress, and childbirth, and a thorough exclusion of these potential confounders is necessary before the Hair Loss can be blamed on the medication. Certain medications are known to cause Hair Loss by a variety of mechanisms including anagen arrest, telogen effluvium, or accentuation of androgenetic alopecia by androgens.
-
female pattern Hair Loss current treatment concepts
Clinical Interventions in Aging, 2007Co-Authors: Quan Q Dinh, Rodney SinclairAbstract:Fewer than 45% of women go through life with a full head of Hair. Female pattern Hair Loss is the commonest cause of Hair Loss in women and prevalence increases with advancing age. Affected women may experience psychological distress and impaired social functioning. In most cases the diagnosis can be made clinically and the condition treated medically. While many women using oral antiandrogens and topical minoxidil will regrow some Hair, early diagnosis and initiation of treatment is desirable as these treatments are more effective at arresting progression of Hair Loss than stimulating regrowth. Adjunctive nonpharmacological treatment modalities such as counseling, cosmetic camouflage and Hair transplantation are important measures for some patients. The histology of female pattern Hair Loss is identical to that of male androgenetic alopecia. While the clinical pattern of the Hair Loss differs between men, the response to oral antiandrogens suggests that female pattern Hair Loss is an androgen dependant condition, at least in the majority of cases. Female pattern Hair Loss is a chronic progressive condition. All treatments need to be continued to maintain the effect. An initial therapeutic response often takes 12 or even 24 months. Given this delay, monitoring for treatment effect through clinical photography or standardized clinical severity scales is helpful.
-
Women who present with female pattern Hair Loss tend to underestimate the severity of their Hair Loss.
The British journal of dermatology, 2004Co-Authors: Sebastiana Biondo, David Stanley Goble, Rodney SinclairAbstract:Summary Background Female pattern Hair Loss (FPHL) is the preferred term for androgenetic alopecia in women. FPHL can be a source of considerable distress for affected women. Our hypothesis was that women with FPHL who seek treatment would rate their condition as more severe than would their treating doctors. Objectives To identify discrepancies between the severity ratings of the women and their clinicians. Methods Participants were 30 women receiving treatment for biopsy-proven FPHL and 44 women on a waiting list to receive treatment for FPHL. Each woman completed a self-report photographic measure of severity of Hair Loss, specifically developed for the current study. Results Although no difference was found between the severity ratings of women receiving treatment and their clinicians, it was found that women in the waiting list group underestimated the severity of their Hair Loss compared with their clinicians' ratings. Conclusion The results indicate that FPHL-affected women who seek treatment for FPHL do not overestimate the severity of the Hair Loss; in fact, they tend to underestimate. The present findings have implications for the treatment of FPHL.
Wilma F. Bergfeld - One of the best experts on this subject based on the ideXlab platform.
-
Diffuse Hair Loss: its triggers and management.
Cleveland Clinic journal of medicine, 2009Co-Authors: Shannon Harrison, Wilma F. BergfeldAbstract:Diffuse Hair Loss can affect both sexes at any age. Anything that interrupts the normal Hair cycle can trigger diffuse Hair Loss. Triggers include a wide variety of physiologic or emotional stresses, nutritional deficiencies, and endocrine imbalances. Loss of telogen-phase Hairs is the most common. Hair Loss during the anagen phase is usually caused by chemotherapy or radiation therapy. Finding the cause, or trigger, of the Hair Loss requires a thorough history and examination and will enable appropriate treatment. Patient education is key in the management of diffuse Hair Loss.
Vladimir A. Botchkarev - One of the best experts on this subject based on the ideXlab platform.
-
p53 Is Essential for Chemotherapy-induced Hair Loss
Cancer research, 2000Co-Authors: Vladimir A. Botchkarev, Elena A. Komarova, Frank Siebenhaar, Natalia V. Botchkareva, Pavel G. Komarov, Marcus Maurer, Barbara A. Gilchrest, Andrei V. GudkovAbstract:Anticancer drugs stimulate apoptosis in the Hair follicles (HF) and cause Hair Loss, the most common side effect of chemotherapy. In a mouse model for chemotherapy-induced Hair Loss, we demonstrate that p53 is essential for this process: in contrast to wild-type mice, p53-deficient mice show neither Hair Loss nor apoptosis in the HF keratinocytes that maintained active proliferation after cyclophosphamide treatment. HF in p53 mutants are characterized by down-regulation of Fas and insulin-like growth factor-binding protein 3 and by increased expression of Bcl-2. These observations indicate that local pharmacological inhibition of p53 may be useful to prevent chemotherapy-associated Hair Loss.
